Laboratory Co. of America Holdings (NYSE:LH) Shares Acquired by Summit Trail Advisors LLC

Summit Trail Advisors LLC increased its stake in Laboratory Co. of America Holdings (NYSE:LH) by 7.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,081 shares of the medical research company’s stock after buying an additional 74 shares during the period. Summit Trail Advisors LLC’s holdings in Laboratory Co. of America were worth $246,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Trust Investment Advisors raised its holdings in Laboratory Co. of America by 1.8% in the fourth quarter. Trust Investment Advisors now owns 2,567 shares of the medical research company’s stock valued at $583,000 after buying an additional 46 shares during the period. Atria Wealth Solutions Inc. raised its holdings in Laboratory Co. of America by 2.8% in the fourth quarter. Atria Wealth Solutions Inc. now owns 1,969 shares of the medical research company’s stock valued at $448,000 after buying an additional 53 shares during the period. Caprock Group LLC raised its holdings in Laboratory Co. of America by 1.8% in the fourth quarter. Caprock Group LLC now owns 3,084 shares of the medical research company’s stock valued at $701,000 after buying an additional 56 shares during the period. Arjuna Capital raised its holdings in Laboratory Co. of America by 3.2% in the third quarter. Arjuna Capital now owns 1,819 shares of the medical research company’s stock valued at $366,000 after buying an additional 57 shares during the period. Finally, Greenleaf Trust raised its holdings in Laboratory Co. of America by 2.5% in the third quarter. Greenleaf Trust now owns 2,559 shares of the medical research company’s stock valued at $514,000 after buying an additional 62 shares during the period. 95.94% of the stock is owned by institutional investors and hedge funds.

Laboratory Co. of America Stock Performance

Shares of LH opened at $201.61 on Thursday. Laboratory Co. of America Holdings has a 1 year low of $174.20 and a 1 year high of $234.09. The company has a market cap of $17.00 billion, a price-to-earnings ratio of 40.57, a price-to-earnings-growth ratio of 1.51 and a beta of 1.02. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.76 and a current ratio of 0.88. The firm has a fifty day moving average of $209.55 and a 200-day moving average of $214.89.

Laboratory Co. of America (NYSE:LH) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $3.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.20. Laboratory Co. of America had a net margin of 3.52% and a return on equity of 14.68%. The company had revenue of $3.18 billion during the quarter, compared to the consensus estimate of $3.12 billion. During the same quarter in the previous year, the company posted $3.82 earnings per share. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. As a group, equities analysts anticipate that Laboratory Co. of America Holdings will post 14.87 earnings per share for the current year.

Laboratory Co. of America Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 12th. Stockholders of record on Tuesday, May 28th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.43%. The ex-dividend date of this dividend is Tuesday, May 28th. Laboratory Co. of America’s dividend payout ratio (DPR) is 57.95%.

Insider Activity

In related news, EVP Der Vaart Sandra D. Van sold 237 shares of Laboratory Co. of America stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $226.45, for a total transaction of $53,668.65. Following the sale, the executive vice president now directly owns 7,637 shares in the company, valued at $1,729,398.65. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Laboratory Co. of America news, CMO Amy B. Summy sold 227 shares of the business’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $218.45, for a total value of $49,588.15. Following the sale, the chief marketing officer now directly owns 3,859 shares in the company, valued at $842,998.55. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Der Vaart Sandra D. Van sold 237 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $226.45, for a total transaction of $53,668.65. Following the completion of the sale, the executive vice president now owns 7,637 shares in the company, valued at $1,729,398.65. The disclosure for this sale can be found here. Over the last quarter, insiders sold 56,985 shares of company stock valued at $12,302,964. 0.85% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on LH shares. TheStreet lowered shares of Laboratory Co. of America from a “b-” rating to a “c+” rating in a research note on Thursday, February 15th. Evercore ISI started coverage on shares of Laboratory Co. of America in a research note on Friday, February 9th. They set an “in-line” rating and a $240.00 price objective on the stock. SVB Leerink started coverage on shares of Laboratory Co. of America in a research note on Monday, February 26th. They set an “outperform” rating and a $260.00 price objective on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of Laboratory Co. of America in a research note on Monday, February 26th. Finally, Robert W. Baird dropped their price objective on shares of Laboratory Co. of America from $255.00 to $244.00 and set an “outperform” rating on the stock in a research note on Friday, April 26th. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $243.14.

Laboratory Co. of America Profile

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).